Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer - 1 Jul 2022

Huang Yong, Ding Haixia, Luo Min, Li Sirui, Xie Conghua, Zhong Yahua, Li Zhiqiang

Abstract excerpt

PURPOSE: We have combined analysis of clinical and laboratory markers to try to find an optimal model to predict venous thromboembolism in isocitrate dehydrogenase 1 (IDH1) wild-type glioblastoma (GBM) by a prospective research. METHODS: Patients with newly histologically confirmed IDH1 wild-type (IDH1wt) GBM were recruited for this study. Status of IDH1, PTEN, P53, BRAF, MGMT promoter methylation (MGMTp), and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Glioblastoma

Share to In Situ Hybridization, Fluorescence

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Venous Thromboembolism

Source

Identifiers

PMID: 35419733
DOI: 10.1007/s00520-022-07050-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined analysis of clinical and laboratory markers to predict the risk of venous thromboembolism in patients with IDH1 wild-type glioblastoma.PMID 35419733Read ↗

Optimizing the Prediction of Venous Thromboembolis by a Risk Assessment Model in Patients with GlioblastomaSemantic proximity Read ↗

Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.Semantic proximity Read ↗

Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.Semantic proximity Read ↗

Targeted DNA sequencing to identify genetic aberrations in glioblastoma that underlie venous thromboembolism; a cohort studySemantic proximity Read ↗

Determining venous thromboembolism risk in patients with adult-type diffuse glioma.Semantic proximity Read ↗

IDH mutation status and the development of venous thromboembolism in astrocytoma patients.Semantic proximity Read ↗

Assessment of venous thromboembolism in adult diffuse-type gliomas: an experience of a quaternary center and a systematic reviewSemantic proximity Read ↗

Mutant IDH1 and thrombosis in gliomas.Semantic proximity Read ↗

Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.Semantic proximity Read ↗

Association between IDH mutational status and tumor-associated epilepsy or venous thromboembolism in patients with grade II and III astrocytoma.Semantic proximity Read ↗

Cancer genetic profile and risk of thrombosis.Semantic proximity Read ↗

Identification of Venous Thromboembolism Driver Genes Based on Integrative Bioinformatics and Machine LearningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.